<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" > <channel> <title> Comments on: China Makes Significant Commitments to Improve Intellectual Property Protection in Phase 1 Trade Deal </title> <atom:link href="https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/feed/" rel="self" type="application/rss+xml" /> <link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/</link> <description></description> <lastBuildDate>Mon, 08 Mar 2021 05:11:28 +0000</lastBuildDate> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.5.2</generator> <item> <title> By: China's Supreme People's Court Releases Provisions on Several Issues Concerning the Application of Law in the Trial of Administrative Cases Concerning Patent Grant and Confirmation - China IP Law Update </title> <link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/#comment-52</link> <dc:creator><![CDATA[China's Supreme People's Court Releases Provisions on Several Issues Concerning the Application of Law in the Trial of Administrative Cases Concerning Patent Grant and Confirmation - China IP Law Update]]></dc:creator> <pubDate>Fri, 18 Sep 2020 22:24:10 +0000</pubDate> <guid isPermaLink="false">http://www.chinaiplawupdate.com/?p=231#comment-52</guid> <description><![CDATA[[…] 22(3) (usefulness) and Article 26(3) (enablement) of the Patent Law. This is to comply with the Phase I Trade Agreement, which stated, “China shall allow drug patent applicants to rely on supplementary data in the […]]]></description> <content:encoded><![CDATA[<p>[…] 22(3) (usefulness) and Article 26(3) (enablement) of the Patent Law. This is to comply with the Phase I Trade Agreement, which stated, “China shall allow drug patent applicants to rely on supplementary data in the […]</p> ]]></content:encoded> </item> <item> <title> By: Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir - China IP Law Update </title> <link>https://www.chinaiplawupdate.com/2020/01/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal/#comment-2</link> <dc:creator><![CDATA[Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir - China IP Law Update]]></dc:creator> <pubDate>Thu, 06 Feb 2020 02:33:05 +0000</pubDate> <guid isPermaLink="false">http://www.chinaiplawupdate.com/?p=231#comment-2</guid> <description><![CDATA[[…] Accordingly, as Remdesivir is unavailable in China and chloroquine is, it seems the Institute’s goal is to enable a cross-license with Gilead and so avoid having the Chinese government invoke compulsory licensing under Articles 48- 50 of the Patent Law, which might cause political repercussions with the U.S. in light on the Phase I trade deal. […]]]></description> <content:encoded><![CDATA[<p>[…] Accordingly, as Remdesivir is unavailable in China and chloroquine is, it seems the Institute’s goal is to enable a cross-license with Gilead and so avoid having the Chinese government invoke compulsory licensing under Articles 48- 50 of the Patent Law, which might cause political repercussions with the U.S. in light on the Phase I trade deal. […]</p> ]]></content:encoded> </item> </channel> </rss>